AVBP ArriVent BioPharma
- 19.910
- +0.090+0.45%
ArriVent BioPharma News
ArriVent BioPharma | 8-K/A: Current report (Amendment)
ArriVent BioPharma | 8-K/A: Current report (Amendment)
ArriVent BioPharma | 8-K: Current report
ArriVent BioPharma | 4: Statement of changes in beneficial ownership of securities-Director Hohneker John
ArriVent BioPharma | 3: Initial statement of beneficial ownership of securities-Director Hohneker John
ArriVent BioPharma | 8-K: Current report
ArriVent BioPharma | 10-Q: Quarterly report
ArriVent BioPharma | 8-K: ArriVent BioPharma Reports First Quarter 2024 Financial Results
ArriVent BioPharma | 4: Statement of changes in beneficial ownership of securities-Director Peterson Kristine
ArriVent BioPharma | 3: Initial statement of beneficial ownership of securities-Director Peterson Kristine
ArriVent BioPharma | 8-K: Current report
ArriVent BioPharma | 8-K: Current report
ArriVent BioPharma | 10-K: Annual report
ArriVent BioPharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-Yi Shi(6.4%),LAV Fund VI, L.P. (“LAVVI”)(6.2%), etc.
ArriVent BioPharma | SC 13D: Statement of acquisition of beneficial ownership by individuals-OrbiMed Advisors LLC(9.1%),OrbiMed Capital GP VIII LLC(4.5%), etc.
ArriVent BioPharma | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
ArriVent BioPharma | 4: Statement of changes in beneficial ownership of securities-10% Owner HILLHOUSE INVESTMENT MANAGEMENT, LTD.
ArriVent BioPharma | 4: Statement of changes in beneficial ownership of securities-Director ORBIMED ADVISORS LLC
ArriVent BioPharma | 4: Statement of changes in beneficial ownership of securities-Director HEALY JAMES
ArriVent BioPharma | 4: Statement of changes in beneficial ownership of securities-Director GORDON CARL L
Analysis
Price Target
No Data
